Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Raf,
So you are saying that lowering of Triclycerides was never a standard of practice. There is nothing complicated about that. If you had bothered to read the link I had provided it certainly states that lowering Trigs was benefitual to interior condition of veins and in turn led to benefits in lowering CVD.
And there in lys the rub. It doesn't take evidence to claim a drug has no benefit, even though it may be proficient in line with a standard of practice, but it is very much more difficult and expensive to actually prove efficacy through a known and already proven benefit. Yet all of this is completely ignored when factoring in the high cost of health care and instead accusing companies of gauging. Something needs to change.
Also, I may point out that it has been a long held belief in the medical community that lowering Tryclycerides has been benefitual for the circulatory system and thus benefitual in preventing associated heart disease. So, the FDA in all of their wisdom has decided that lowering Trigs is no longer benefitual based on what evidence?
http://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/triglycerides/ART-20048186?pg=2
I am certain that there exist much disagreement with their hypothesis. Because that is all it is.
HDG,
You may be right about no science, since the FDA stated that in two other trials with other products that lowering Trigs showed no benefit for CHD. You call it no science, I call it faulty science. The results of the Mayo Clinic report stated that lowering Trigs was indeed beneficial. Since we are dealing with results from observing 100's of thousands of patients I would put far more credence in their finding that some lazy bureaucrats who may or may not have alternative motives.
Might not be a bad time to at the least have the lawyers threaten to sue for damages if the FDA does not immediately rescind their Anchor decision. Amarin has done everything the FDA has requested at great financial loss and should be compensated. The science the FDA used to rescind Anchor was questionable and research since that time has proven that fact.
If they are clear capsules place them in the freezer. If they come out looking cloudy then they are not pure and contain contaminantes. Simple test.
If you believe that last sentence you are certifiably nuts.
I have heard people say it was a missile that hit the Pentagon and when I informed them I had a friend at a meeting in Crystal City who was astonished to see the airliner fly so low past his conference room window that day they still held to their convictions. I determined then that no evidence will change certain people's minds because they believe what they want to believe. Sorry.
Sounds very familiar........
Those that bet against Amarin are acting like the never Trumpers. Learn to deal with it. The new direction for treating heart disease is prevention and what better way to accomplish that than Omega 3's.
He is working the buyers end while this guy works with the Amarin end.
http://www.sofinnova.com/team_detail.php?sort=all&id=40
Thanks, I think I figured it out. I am just trying to figure out Amarin's involement with the Put Options, if any.
So in your opinion removing the protection of these put options before RI results are lnown will not have an effect on the S/P.
Why no discussion of Amarin decision to call in the put option notes now ?
The Jelis study was made up of individuals of Japanese discent. Historically they eat a lot of fish, generation upon generations. I believe EPA is well embedded in their make up and taking EPA dosages can trigger a much better response to its benefits. The benefits of EPA are much better over time as it builds up in your body. AJMO.
Amarin Gaining Popularity among Hedge Funds.
Owned by 19 hedge funds in 3rd quarter vs 12 in second.
http://www.insidermonkey.com/blog/do-hedge-funds-love-amarin-corporation-plc-adr-amrn-501229/?yptr=yahoo
Guess the V Day" contest #2
Feb.23/Aug.16/ 28%
When stocks are volatile it is simply because some investors are playing the S/P gaps while playing on investor fears and emotions which increasingly makes it more volatile. This stock will make a gradual increase into Feb earnings with many ups and downs and will not be stable until well after RI? I don't believe T/A can accurately predict stocks awaiting events. T/A is all about investor attitudes and confidence or lack thereof of normally stable stocks. Amarin is being played with too much to gauge it accurately. JMO.
"Natural gas is expected to make up a larger share of total U.S. electricity generation than coal for the first time ever. The shuttering of coal plants and the construction of new natural gas plants will lock in gas demand for years – and likely, decades – to come.........The recent OPEC deal complicates this picture. Before the deal to cut output, oil prices were expected to remain more or less where they are – the EIA projected WTI to average just under $50 per barrel through 2017. But the sharp increases in prices in recent days, and the prospect of further gains for crude in the months ahead, likely means that shale drillers will rush back to work. That will probably lead to a rebound in oil production sooner rather than later – and a likely side effect of that will be a rise in natural gas production.
“These guys will drill more, and you are going to get that extra gas at an inconvenient time,” Jason Schenker, president of Prestige Economics LLC, told Bloomberg in an interview. “It’s bearish for U.S. gas for the next three- to nine-month window.”
That remains to be seen. In the short run, due to a tightening of supply and demand, we could see natural gas prices consistently trading north of $3/MMBtu for the first time in more than two years."
.....
Great for GE but also Capstone. More gas demand equates to more drilling and infrastructure expansion which will bode well for Capstone.
It was all about Obama Care and cheaper meds and targeting smaller companies with much less, if any, political influence and money to fight back. Why would Vascepa be held to such extreme and expensive scrutiny as far more dangerous drugs. The safety profile of Vascepa is well known, just not the efficacy. The FDA tried to tie safety and efficacy together in the off label case and the judge didn't buy it.
Perhaps it is because of the notes conversion? It would reflect a much larger shares holding. Off thr top of my head they had 4 million shares for under $2.00 per share and now have 24 million worth $3.45.
STS,
Yes, I noticed that and have since posted a correction. Thank you for picking up on that also. Baker Bros have done very well in their investment of Amarin. Up over 2400%. It's a shame that they posted the wrong figures, that little article could otherwise generate a lot of interest in Amarin.
Baker Bros. holdings in Amarin
http://www.insidermonkey.com/insider-trading/company/amarin+corp+plcuk/897448/hedge-funds/
Apparently, the header in the article I had previously posted was wrong.
HEDGEDGE FUNDS-NEWS
The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
http://www.insidermonkey.com/blog/the-healthcare-gurus-at-baker-bros-advisors-were-buying-these-stocks-in-q3-491116/
Trump will initiate fracking on gov't owned property which will greatly expand the industry and benefIt Capstone enormously. Also more business from Russia will be coming Capstones way as relations between our countries improve. Rebuilding America"s infrastructure will include pipelines to get oil and gas to markets more efficiently. Good days ahead for Capstone. AJMO.
Some will take advantage of stops today when no one is home. Could go much lower because today is a busy travel day. We'll see. Beware though because Monday could be a big buying day.
I think it will gradually drop to the 3.30s leading up to Thanksgiving holiday.
$3.80 in pre-market. I don't know how many shares since I don't have access to level II at this time.
Sorry for your losses.
There are more than likely some want to be Trumpers already working at the FDA who know very well what the FDA has been up to regarding Vascepa and many other drug candidates.
915,915 purchase at 3.40 P/S at 16:00
Tomorrow should be another good day JMO.
Yahoo, such a reliable source. Lol.
Amarin Corporation plc (AMRN) -NasdaqGS ? Watchlist
3.28 Up 0.12(3.80%) Nov 14, 4:00PM EST
Pre-Market : 3.35 Up 0.07 (2.13%)
Up to $3.37 in pre market
Baker Bros seem to know well before the rest of us. In conjunction with the Trump comments let the PR campaign begin. Anchors away, smooth sailing ahead, mates.
tVascepa® (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Parameters in Statin-Treated Women with Persistent High Triglycerides
Amarin Corporation plc
9 hours ago
GlobeNewswire
????
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN) today announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women with persistent high triglyceride levels.
The presentation of additional data from the ANCHOR study showed, consistent with overall study results, that prescription pure EPA Vascepa® (icosapent ethyl) reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers in a subgroup of statin-treated women with persistent high triglycerides. The post hoc analysis supporting the efficacy of pure, prescription icosapent ethyl in this patient population was presented as an oral abstract (#309) titled, “Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Women With Persistent High Triglycerides: Results From the ANCHOR Study.”
The analysis is published in the American Journal of Cardiology; an early version of the manuscript is accessible at http://www.ajconline.org/article/S0002-9149(16)31738-6/pdf.
The analysis was led by Lori Mosca, MD, MPH, PhD, Professor of Medicine Emerita and Center Director of the American Heart Association Go Red for Women Research Network at Columbia University Medical Center, New York. Researchers observed that compared to placebo, Vascepa administered at 4 g/day significantly reduced triglycerides (TGs) without increasing LDL (“bad”) cholesterol in women from the ANCHOR study with TG levels between 200 to 499 mg/dL. In addition, statistically significant improvements were observed in numerous potentially atherogenic parameters (lipids and lipoproteins) and inflammatory markers.
"It is important to generate data that address the specific needs of women, especially in fields where the data could prove useful to patient care," said Dr. Mosca. “While further study is needed and ongoing, this analysis is encouraging because the efficacy and safety of Vascepa 4 g/day in this subgroup of 91 statin-treated women with persistent high triglycerides were consistent with the overall ANCHOR results, which included 702 patients. It is vitally important to evaluate both potential benefits and side effects of therapies in women and not assume results from men are similar in women."
The clinical implications of lowering triglycerides with Vascepa 4 g/day are being investigated in the REDUCE-IT cardiovascular outcomes study of statin-treated women and men with persistent elevated TG levels.
The ANCHOR study and post hoc analysis were sponsored by Amarin and were not affiliated with or funded by the American Heart Association (AHA) or the AHA Go Red for Women Research Network.
About the Presented Research
Dr. Mosca’s analysis was based on a post hoc subgroup analysis of 179 women in the ANCHOR trial, a study that investigated Vascepa as a treatment for patients with residual high TG (≥200 and <500mg/dL) despite statin-induced control of LDL-C. ANCHOR enrolled 702 patients, of which the majority (73%) had Type 2 diabetes. The primary endpoint was percent change in TG levels from baseline to 12 weeks compared with placebo in subjects treated with placebo or Vascepa at 2 or 4 g/day. In April 2011, Amarin reported top-line results from the ANCHOR trial, which met its primary and secondary endpoints.
The subgroup analysis presented at the American Heart Association Scientific Sessions 2016 evaluated the efficacy of Vascepa on TG levels, potentially atherogenic (lipid and lipoprotein) parameters and inflammatory markers among a subgroup of women (97% white, 82% with diabetes, mean age 62 years) that were randomized to receive either Vascepa 4 g/day (n=91) or placebo (n=88) from baseline to week 12.
The analysis showed that, compared to placebo, Vascepa significantly reduced TGs (-22%; P<0.0001) without increasing LDL-C (-6%; P>0.05). Significant improvement in other potentially atherogenic parameters (non-HDL-C, VLDL-C, VLDL-TG, apoB, RLP-C) and inflammatory markers (Ox-LDL, Lp-PLA2, hsCRP) were also observed vs. placebo (P<0.05 for all).
As with many subgroup analyses, a limitation is the small sample size, but the results are nonetheless suggestive of complementary beneficial changes in TG levels and other potentially atherogenic parameters and inflammatory markers as compared with placebo. The efficacy and safety of Vascepa 4 g/day in women were consistent with the overall ANCHOR results.
Amarin's clinical development program for Vascepa includes a trial known as REDUCE-IT. REDUCE-IT is a global Phase 3, randomized, multicenter, double-blind, placebo-controlled study designed to evaluate whether treatment with Vascepa reduces cardiovascular events in patients who despite stabilized statin therapy have elevated triglyceride levels and other cardiovascular risk factors. The primary endpoint of the study is the time to the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction (heart attack), nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. Secondary endpoints include time to event analyses of components of the primary endpoint. The study is being conducted under a special protocol assessment agreement with the FDA.
Additional information on ANCHOR, REDUCE-IT and Amarin's other clinical studies of Vascepa can be found at www.clinicaltrials.gov.
Yes,
And any shares awarded are taxed at the value when awarded no matter the current price so it is wise to regularly sell shares to stay current with ones taxes.
You were dreaming pleasant dreams yesterday.......
Now today it is time to wake up and get excited since Trump has won the election. Good things for Capstone will be happening. Lower Corporate tax rates and even more importantly the oil and natural gas production will increase dramatically. Short term, Russian buyers for their products starting in Jan., 2017. Should be a great buying time for CPST shares. AJMO.
You have 6 months to a year until the next significant event (R-it). Dead money until then. Unfortunately, the S/P will creep down until then. There does exist the possibility of a tremendous earnings report, or a partnership but both of those are highly unlikely until after R-It. Sorry.
Got to be either associated with, or a friend of Hilary and the Obamas. When you have the DOJ as a friend it emboldens you to do whatever you want.
BB,
Commenting on the quote you provided I would have to say Woodcock and Hilary probably had the same lying, deceitful Rhetoric professor in college. It is true that a teacher never knows where their influence will end but that is not always a good thing. Lol.
20 years of following stocks and trends. However, I am a little concerned about the figures Sam posted this AM. It may affect long investors growing confidence levels. Day traders could care less about such things, they are just looking for momentum, but long term investors do and if they become concerned about something affecting growth, such as tier level changes they may decide to cash out and they are the foundation which effects everything else.
Raf,
Tomorrow will be a big buying day. (or Monday)
10 Stocks with massive upside projections:
"Amarin Corp. PLC (NASDAQ: AMRN) was started as Buy with a $5 price target at Citigroup on October 19. Shares had closed at $3.00 prior to the report, and they ended the week at $3.20. The 52-week range is $1.24 to $3.46, and Amarin now has a $658 million market cap. The consensus price target is $6.30, so maybe this massive 56% in remaining implied upside is not entirely out of the question."
http://247wallst.com/investing/2016/10/23/10-analyst-stocks-under-10-with-massive-upside-projections/?yptr=yahoo
Yes,
I saw that at the link bio bill provided.